Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2221
Source ID: NCT02266030
Associated Drug: Cilostazol
Title: Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM
Acronym: ESCAPE
Status: COMPLETED
Study Results: NO
Results:
Conditions: Coronary Artery Disease
Interventions: DRUG: Cilostazol|DRUG: Aspirin
Outcome Measures: Primary: Coronary artery stenosis, Severity of coronary artery stenosis (%), one year | Secondary: Plaque characteristics, Noncalified plaque, one year|Plaque characteristics, Mixed plaque, one year|Plaque characteristics, Calcified plaque, one year|Multivessel involvement, Multivessel involvement in coronary arteries, one year|Main vessel involvement, Left main and/or proximal LAD stenosis, one year|Coronary artery calcium (CAC) score, Agatston score for CAC, one year|Glucose homeostasis, Changes in HbA1c, one year|Glucose homeostasis, Changes in fasting glucose concentration, one year|Lipid metabolism, Changes in TG concentration, one year|Lipid metabolism, Changes in HDL-concentration concentration, one year | Other: Bleeding risk, Any type of bleeding, one year|Headache, Any type of headache, one year|Heart rate, Frequence of heart beat per min, one year
Sponsor/Collaborators: Sponsor: Seoul National University Bundang Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 100
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2011-02
Completion Date: 2016-11
Results First Posted:
Last Update Posted: 2017-10-09
Locations: Seoul National University Bundang Hospital, Seongnam, Bundang-gu, 463-707, Korea, Republic of
URL: https://clinicaltrials.gov/show/NCT02266030